Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2024 | Comparing experiences of patients with SCD in developed and developing countries: UK versus India

Sanne Lugthart, MD, PhD, University Hospitals of Bristol and Weston NHS Foundation Trust, Bristol, UK, discusses a comparison of patient experiences with sickle cell disease (SCD) in developed and developing countries, highlighting differences in physiological measures and patient-reported outcomes (PROs) between patient cohorts from the United Kingdom and Indian. Dr Lugthart notes that the UK cohort had higher levels of symptom severity, while the Indian cohort had a higher EQ-5D score. She emphasizes the need to explore the underlying causes of these differences, including environmental and healthcare system factors. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.